fibrinogen, human

Drug Overview

Human Fibrinogen is a highly specialized, plasma-derived biological therapy within the hematology category. Classified as Coagulation Factor I, it is a critical, life-saving medication used to manage severe bleeding in patients who are genetically missing the proteins required to form stable blood clots. By providing a purified concentrate of the missing protein, it offers a much safer and more efficient alternative to massive transfusions of fresh frozen plasma (FFP) or cryoprecipitate.

• Generic Name / Active Ingredient: Fibrinogen, human (Coagulation Factor I)
• US Brand Names: RiaSTAP, Fibryga
• Drug Class: Blood Product Derivative / Human Blood Coagulation Factor
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Fully FDA-approved for pediatric and adult patients with specific congenital bleeding disorders.

What Is It and How Does It Work? (Mechanism of Action)

To understand how human fibrinogen works, you have to look at the human body’s “coagulation cascade”—the complex chain reaction that stops bleeding.

Fibrinogen (Factor I) is a vital, water-soluble protein naturally produced by a healthy liver. When a blood vessel is injured, the body triggers an enzyme called thrombin. Thrombin’s job is to convert the circulating, liquid fibrinogen into long, sticky, insoluble threads of fibrin. These fibrin threads weave together like a net, catching blood cells and platelets to form a stable, solid clot that permanently stops the bleeding.

Patients with congenital deficiency are born with a genetic mutation that prevents their liver from making enough . When they bleed, their blood cannot form the final fibrin net, leading to uncontrolled hemorrhage.

Medications like RiaSTAP or Fibryga act as a direct, highly purified replacement therapy. Manufactured from pooled human blood plasma, they provide the exact missing protein. When infused intravenously during a bleeding episode, the drug rapidly restores the patient’s circulating levels, allowing the body to complete the coagulation cascade and achieve rapid hemostasis (the cessation of bleeding).

FDA-Approved Clinical Indications

Primary Indication

Human fibrinogen concentrates are specifically indicated for the treatment of acute bleeding episodes in pediatric and adult patients with Congenital Deficiency (CFD), which includes:

• Hypofibrinogenemia: Abnormally low levels of circulating fibrinogen.
• Afibrinogenemia: A complete absence of fibrinogen in the blood.

(Note: Certain newer formulations, like Fibryga, are also explicitly FDA-approved for perioperative prophylaxis—preventing bleeding during scheduled surgeries—in these same patients.)

Limitations of Use

• These products are explicitly not indicated for dys (a condition where fibrinogen is present in normal amounts but is functionally defective).

Dosage and Administration Protocols

Because human is used to manage acute bleeding, dosing must be highly individualized. It is supplied as a sterile, lyophilized powder that must be reconstituted with sterile water before use.

Important Administration Rules:

• Infusion Rate: It must be infused slowly via an IV line. The maximum recommended infusion rate varies slightly by brand but is typically 5 mL per minute for adults and older children.
• No Mixing: Fibrinogen must be administered via a separate, dedicated IV line and cannot be mixed with any other intravenous medications or fluids (except saline).

Clinical Efficacy and Research Results

Before the approval of purified fibrinogen concentrates, patients experiencing bleeding emergencies had to rely on time-consuming transfusions of cryoprecipitate or fresh frozen plasma.

Clinical trials demonstrated that purified human provides a highly predictable, rapid restoration of target fibrinogen levels without overloading the patient’s circulatory system with massive fluid volumes. Because it is highly concentrated, it achieves hemostasis much faster, which is considered a critical survival advantage during severe traumatic injuries, intracranial hemorrhages, or complex emergency surgeries.

Safety Profile and Side Effects

Serious Warnings and Precautions

• Thrombosis Risk: Because this drug powerfully promotes blood clotting, there is a serious risk of thrombotic events (unwanted, dangerous blood clots forming inside the blood vessels). This includes deep vein thrombosis (DVT), pulmonary embolism, and myocardial infarction. Clinicians must carefully weigh the benefits of stopping the bleed against the risk of causing a systemic clot.
• Hypersensitivity Reactions: Severe allergic reactions, including fatal anaphylaxis, can occur. If a patient develops hives, chest tightness, wheezing, or low blood pressure during the infusion, it must be stopped immediately.
• Pathogen Transmission: Because it is derived from pooled human plasma, it carries a theoretical risk of transmitting blood-borne infectious agents (such as viruses or the Creutzfeldt-Jakob disease agent), despite rigorous donor screening, pasteurization, and viral inactivation processes.

Common adverse reactions (>1%)

• Fever (pyrexia)
• Headache
• Nausea or vomiting
• Chills

Ongoing Research Area: Acquired Fibrinogen Deficiency in Massive Hemorrhage

While currently approved exclusively for genetic, congenital fibrinogen deficiencies, hematology and trauma research is heavily focused on expanding the use of purified concentrates into critical care and trauma settings. Clinical trials are actively investigating its efficacy in treating acquired deficiency. This occurs when patients with normal genetics lose massive amounts of blood—and thereby deplete their natural during complex cardiovascular surgeries, severe postpartum hemorrhage, or massive traumatic injuries. Researchers aim to determine if utilizing targeted concentrate rather than high-volume fresh frozen plasma (FFP) can more rapidly and effectively halt catastrophic bleeding while reducing transfusion-related circulatory overload (TACO).

Disclaimer

The research discussed regarding the use of human fibrinogen concentrate for the management of acquired deficiency in severe trauma, postpartum hemorrhage, or major surgical settings is currently in the investigational phase and is not yet applicable to practical or professional clinical scenarios outside of approved clinical trials.

Patient Management and Practical Recommendations

Pre-treatment and Procedural Monitoring

• Baseline Diagnostics: Whenever possible, without delaying life-saving treatment, baseline plasma levels should be drawn before the infusion to accurately calculate the required dose.
• Vigilant Observation: Patients must be closely monitored during and after the infusion for any signs of an allergic reaction or unexpected thromboembolic events (such as sudden chest pain, shortness of breath, or localized leg swelling).

“Do’s and Don’ts” List (For Healthcare Providers)

• Do ensure the lyophilized powder and the sterile water diluent are brought to room temperature before reconstitution.
• Do gently swirl the vial to dissolve the powder; don’t vigorously shake it, as this can denature the delicate proteins and cause excessive foaming.
• Visually inspect the reconstituted solution; it should be colorless to pale yellow and slightly opalescent.
• Don’t use the solution if it is cloudy, heavily turbid, or contains visible particulate matter.
• Don’t allow blood from the patient to back up into the syringe or IV tubing containing the drug, as this can cause an immediate, dangerous fibrin clot to form inside the line.

Legal Disclaimer

For informational purposes only; this document does not replace professional medical advice from a qualified healthcare provider. This content is not intended to be a substitute for professional medical diagnosis, treatment protocols, or clinical judgment. Always seek the advice of your hematologist or emergency care physician with any questions you may have regarding rare bleeding disorders or before altering any prescribed medication regimen.